Who
Karin Jooss
Director
Company insider
Files Form 4 as: Director, Fate Therapeutics; Officer, Gritstone bio.
In numbers
- Trades disclosed
- 25
- Buys
- 0
- Sells
- 2
- Bought
- $0
- Sold
- $44K
- Companies
- 2
- Companies where not an officer
- 1
- First trade
- 13 Feb 2019
- Last trade
- 12 Jun 2026
- Last filed
- 15 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 12 Jun 2026filed 15 Jun 2026 | FATE Fate Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —87,900 at $0.00 | filing |
| 12 Jun 2026filed 15 Jun 2026 | FATE Fate Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —87,900 at $0.00 | filing |
| 29 May 2025filed 30 May 2025 | FATE Fate Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —55,000 at $0.00 | filing |
| 7 Jun 2024filed 11 Jun 2024 | FATE Fate Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 16 May 2024filed 17 May 2024 | Gritstone bio | SEC FORM 4 Sold | $10K13,749 at $0.75 | filing |
| 15 May 2024filed 17 May 2024 | Gritstone biooption or derivative | SEC FORM 4 Code A | —235,000 at $0.00 | filing |
| 15 May 2024filed 17 May 2024 | Gritstone bio | SEC FORM 4 Code A | —27,128 at $0.00 | filing |
| 1 Feb 2024filed 5 Feb 2024 | Gritstone biooption or derivative | SEC FORM 4 Code A | —235,000 at $0.00 | filing |
| 1 Feb 2024filed 5 Feb 2024 | Gritstone bio | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 6 Jun 2023filed 7 Jun 2023 | FATE Fate Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 2 Feb 2023filed 6 Feb 2023 | Gritstone bio | SEC FORM 4 Code A | —252,763 at $0.00 | filing |
| 9 Jun 2022filed 13 Jun 2022 | FATE Fate Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —11,893 at $0.00 | filing |
| 9 Jun 2022filed 13 Jun 2022 | FATE Fate TherapeuticsBiotechnology | SEC FORM 4 Code A | —8,650 at $0.00 | filing |
| 3 Jun 2022filed 6 Jun 2022 | FATE Fate TherapeuticsBiotechnology | SEC FORM 4 Sold | $34K1,483 at $22.82 | filing |
| 31 Jan 2022filed 20 Apr 2022 | Gritstone biooption or derivative | SEC FORM 4 Code A | —165,600 at $0.00 | filing |
| 31 Jan 2022filed 20 Apr 2022 | Gritstone bio | SEC FORM 4 Code A | —27,600 at $0.00 | filing |
| 2 Jun 2021filed 4 Jun 2021 | FATE Fate TherapeuticsBiotechnology | SEC FORM 4 Code A | —2,681 at $0.00 | filing |
| 2 Jun 2021filed 4 Jun 2021 | FATE Fate Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —4,334 at $0.00 | filing |
| 8 Mar 2021filed 10 Mar 2021 | Gritstone Oncologyoption or derivative | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
| 7 Jan 2021filed 19 Nov 2021 | Gritstone bio | SEC FORM 4 Code A | —27,900 at $0.00 | filing |
News
Analyzing Fate Therapeutics (NASDAQ:FATE) & Applied Therapeutics (NASDAQ:APLT)FATE · dailypolitical.com · 19 Oct 2026
0 headlines in the last 90 days name Karin Jooss; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.